FDA Drug Review Costs Rise, But Personnel Spending Flattens
Executive Summary
Less than 60% of the total spending on reviews was attributed to employee compensation and benefits in FY 2011. FDA says it is normal, but the figure is lower than costs seen in recent years.
You may also be interested in...
Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA
While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.
Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA
While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.
Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says
Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.